Kyntra BIO vs Ocugen
Kyntra BIO is the larger business, with $6.4m of revenue in fiscal 2025 against $4.4m for Ocugen (1.5 times as much). Ocugen grew faster (8.8% against -78.3%). Kyntra BIO kept more of each dollar of sales as profit: a net margin of 2848.6% against -1537.4%.
| Latest fiscal year | Kyntra BIOKYNB, 2025 | OcugenOCGN, 2025 |
|---|---|---|
| Revenue | $6.4m | $4.4m |
| Revenue growth | -78.3% | 8.8% |
| Net income | $183m | −$67.8m |
| Operating margin | -712.7% | -1425.7% |
| Net margin | 2848.6% | -1537.4% |
| Return on equity | — | — |
| Free cash flow | −$4.8m | −$57.1m |
| Cash | $47.9m | $18.6m |
| Total debt | $0 | $31.5m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 34 | 116 |
| Market value | $17.5m | $253m |
| Price vs our value range | — | — |
| Moat score | 11 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 4 buys, 0 sales | 1 buys, 4 sales |